TABLE 1.

Baseline characteristics of Medicaid beneficiaries ages 18–64 who were retained on buprenorphine for ≥180 days, by treatment duration cohort^a

		Treatment Duration Cohort

Characteristic	Total	6–9 months		9–12 months		12–15 months		15–18 months

	N	N	%	N	%	N	%	N	%

	8,996	4,126	45.9	2,440	27.1	1,499	16.7	931	10.3
Sex
Male	3,512	1,641	39.8	934	38.3	583	38.9	354	38.0
Female	5,484	2,485	60.2	1,506	61.7	916	61.1	577	62.0
Age group (years)
18–24	966	462	11.2	258	10.6	157	10.5	89	9.6
25–34	4,473	2,072	50.2	1,210	49.6	718	47.9	473	50.8
35–44	2,400	1,079	26.2	654	26.8	418	27.9	249	26.7
45–54	856	375	9.1	241	9.9	151	10.1	89	9.6
55–64	301	138	3.3	77	3.2	55	3.7	31	3.3
Race/ethnicity
White	8,234	3,772	91.4	2,220	91.0	1,372	91.5	870^*	93.4
Nonwhite	762	354	8.6	220	9.0	127	8.5	61^*	6.6
Medicaid plan type
Fee for service	2,681	1,237	30.0	762	31.2	409^*	27.3	273	29.3
Capitation	6,315	2,889	70.0	1,678	68.8	1,090^*	72.7	658	70.7
Psychiatric diagnosis	2,777	1,273	30.9	764	31.3	454	30.3	286	30.7
Substance use diagnosis
Alcohol use disorder	430	205	5.0	107	4.4	77	5.1	41	4.4
Nonopioid drug use disorder	1,951	931	22.6	517	21.2	308	20.5	195	20.9

	Mean	Mean	SD	Mean	SD	Mean	SD	Mean	SD

Initial buprenorphine dosage (mg/day)	8.0	7.9	2.3	8.0	2.3	8.2^**	2.4	8.2^**	2.4

Data are from the multi-state MarketScan database of Medicaid claims, 2013–2017.

p<0.05.

^**

p<0.01.